Jump to content

Talk:Sinopharm BIBP COVID-19 vaccine

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia


Requested move 12 August 2021

[edit]
The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved to Sinopharm BIBP COVID-19 vaccine and Sinopharm WIBP COVID-19 vaccine. per discussion consensus and consistency policies. (non-admin closure) — Shibbolethink ( ) 15:22, 26 August 2021 (UTC)[reply]


– Following WP:MEDTITLE and WP:MEDORG, the World Health Organization seems to prefer Sinopharm BIBP[1] and Sinopharm WIBP[2] over BBIBP/BBIBP-CorV and WIBP-CorV. English-speaking media mostly uses Sinopharm vaccine, ignoring the existence of WIBP-CorV. If this request is approved, then naturally WIBP-CorV would be moved to Sinopharm COVID-19 vaccine WIBP for consistency. Fernando Trebien (talk) 20:27, 12 August 2021 (UTC) — Relisting. D🐶ggy54321 (let's chat!) 21:16, 19 August 2021 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

Semi-protected edit request on 10 September 2021

[edit]

change "emergency used authorization" to "emergency use authorization" 2001:EE0:1A1:5484:7280:4C94:88BE:3F67 (talk) 18:14, 10 September 2021 (UTC)[reply]

 Done Extraordinary Writ (talk) 04:59, 11 September 2021 (UTC)[reply]

Wrong information

[edit]

Authorizations . . . On 5 May 2021, EMA's human medicines committee (CHMP) has started a rolling review of the vaccine. The EU applicant for this medicine is the Italian company Life'On S.r.l.[84]

There is no ongoing EMA Rolling Review for Sinopharm BIBP-CorV. The information stated in literature reference 84 relates to the vaccine CoronaVac from SinoVac. --Benedikt.ebli (talk) 19:38, 2 February 2022 (UTC)[reply]

Antibody Response to Sinopharm COVID-19 Vaccine in Cancer Patients:

[edit]

[In 2021, a cross-sectional study was conducted on 74 patients with various types of cancers in Iran. These patients had received two doses of the Sinopharm vaccine. The study measured levels of SARS-CoV-2 neutralizing antibodies, Anti-RBD, and Anti-Spike IgG for 4 to 6 weeks after the second vaccine dose. Positive neutralizing antibody status was observed in 41 individuals (55.4%). Additionally, 31 people (41.9%) tested positive for antibodies against RDB antigen, and 20 people (27%) had antibodies against Spike virus antigen. ref: https://jmums.mazums.ac.ir/article-1-20689-en.html] Reza nava (talk) 16:40, 2 May 2024 (UTC)[reply]